NEW YORK – Swiss life science informatics firm Genedata said Monday that it has been acquired by Danaher for an undisclosed amount.
The acquisition is expected to add to Danaher's tools for drug discovery, development, and manufacturing and follows several previous collaborations between the two companies.
Basel-based Genedata offers software targeted at the biopharma R&D market, providing tools for automating and managing data processes for various technologies. They include Genedata Selector for next-gen sequencing-based cell line development and Genedata Expressionist for mass spectrometry workflows.
"Genedata is a global market leader in digitalizing R&D processes to help accelerate the delivery of lifesaving and personalized medicines," Othmar Pfannes, the company's founder and CEO, said in a statement. "As a Danaher operating company, Genedata will seek to continue to attract the brightest talent and solve our customers’ hardest problems globally."
"Throughout our trusted relationship with Genedata, we have long admired their innovative software systems anchored in deep scientific expertise," Greg Milosevich, VP and group executive of Danaher's DH Life Sciences subsidiary, said in a statement. "We share a commitment to supporting biopharma companies to accelerate the development of much-needed therapies by providing innovative solutions that help researchers access high-quality insights."